Ontology highlight
ABSTRACT:
SUBMITTER: Planchard D
PROVIDER: S-EPMC11021522 | biostudies-literature | 2024 Apr
REPOSITORIES: biostudies-literature
Planchard David D Sanborn Rachel E RE Negrao Marcelo V MV Vaishnavi Aria A Smit Egbert F EF
NPJ precision oncology 20240416 1
In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. The BRAF<sup>V600E</sup> mutation confers constitutive activity of the MAPK pathway, leading to enhanced growth, proliferation, and survival of tumor cells. Testing for BRAF mutations enables patients to be treated with therapies that directly target BRAF<sup>V600E</sup ...[more]